Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Paris, October 25, 2024
Q3 sales growth of 15.7% at CER and business EPS
(1)
of €2.86
Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmed
Pharma launches up 67.1% to €727 million, led by ALTUVIIIO,...
Zur Pressemeldung auf www.sanofi.com